AUSTIN, Texas, May 16, 2016 /PRNewswire/ -- Luminex Corporation
(NASDAQ: LMNX) today announced it will highlight the latest
additions to its product portfolio at the 32nd Annual
Clinical Virology Symposium, a meeting of the American Society for
Microbiology, taking place May 19-21
in Daytona Beach, Florida. The new
ARIES® System will be featured in seven poster presentations, and
showcased in a company-sponsored workshop. The recently FDA-cleared
and CE-marked NxTAG® Respiratory Pathogen Panel (RPP) will be
featured in eight posters. More information, including a select
list of Luminex-related posters and events, is available
online.
![The ARIES(R) System is Luminex's new solution for real-time PCR molecular testing, designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory. The ARIES(R) System is Luminex's new solution for real-time PCR molecular testing, designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory.](https://photos.prnewswire.com/prnvar/20160516/367923)
The ARIES® System is Luminex's new solution for
real-time PCR molecular testing, designed to increase laboratory
efficiency, ensure result accuracy, and fit seamlessly into today's
lean laboratory. The ARIES® System is the most powerful and
intuitive of any sample to answer solution for molecular testing,
and provides complete control of the testing process from sample
accessioning to results reporting. Luminex offers a
number of assay panels for use with the system, including the
CE-IVD marked ARIES® HSV 1&2 Assay, and the GBS and Flu
A/B & RSV Assays available for research use. The ARIES® System
and ARIES® HSV 1&2 Assay received FDA clearance
in October 2015 and were subsequently launched in the
U.S. market.
Since its introduction, numerous labs have begun implementing
the ARIES® System for their diverse molecular testing needs. In the
product workshop, three distinguished speakers will present studies
performed in their laboratories using the ARIES® System:
- Dr. Anami Patel, from Poplar
Healthcare, will describe a study to evaluate ARIES® HSV
performance and workflow as compared to another commercially
available assay and a laboratory developed test (LDT) for HSV;
- Dr. Ted Schutzbank, from St.
John Hospital and Medical Center, will present the results of an
ARIES® LDT for varicella zoster virus (VZV) using ASRs in
comparison with a TaqMan-based VZV LDT;
- Dr. Xiaotian Zheng, from Ann
& Robert H. Lurie Children's Hospital of Chicago, will discuss his ARIES® LDT
using analyte specific reagents (ASRs) for detection of enterovirus
in pediatric blood samples for early diagnosis of
meningitis/encephalitis and sepsis.
The workshop will take place on Friday,
May 20, 2016 from 1:30 PM-3:00
PM in the Hilton Daytona Beach Resort Oceanwalk Village.
Interested individuals can register here.
At the Symposium, Luminex employees will demonstrate new
software called SYNCT™ and other tools in a unique "Experience
Room." The room will be contained within
the Luminex booth (#227) on the trade show floor, which
will also include the ARIES® System, MAGPIX® instrument,
and NxTAG RPP assay. SYNCT software streamlines data
analysis and reporting, and is specifically designed for the needs
of molecular labs running ARIES® or NxTAG RPP assays to allow
lab directors to manage their lab data from multiple workstations
through a single interface.
"We are excited to come to this year's CVS conference with a
powerful suite of new tools to support scientists and physicians
working on the front lines to fight viral infections and other
infectious diseases," said Eric
Shapiro, Vice President, Global Marketing, Luminex
Corporation. "Our solutions enable clinical laboratories to operate
at a new standard of efficiency through seamless integration of
both syndromic and targeted testing, resulting in improved patient
outcomes."
About the ARIES® System and HSV 1&2 Assay
The ARIES® System is a sample to answer molecular diagnostic
system designed to increase laboratory efficiency, ensure result
accuracy, and fit seamlessly into today's lean laboratory
environment. The ARIES® System uses internal barcode
scanning and other advanced features to minimize operator errors.
Two independent modules each support from one to six cassettes,
allowing for both STAT and Batch testing of IVD and homebrew assays
using MultiCode® Reagents when using a common Universal Assay
Protocol. An integrated touchscreen PC eliminates the need for a
separate computer, standalone keyboard, and mouse, maximizing
valuable bench space.
The ARIES® HSV 1&2 Assay is a real-time PCR-based
qualitative in vitro diagnostic test for the
direct detection and typing of herpes simplex virus (HSV 1&2)
DNA in cutaneous or mucocutaneous lesion specimens from symptomatic
patients, or in cerebrospinal fluid (CSF) from patients suspected
of HSV infections of the central nervous system. The test is
indicated for use with symptomatic individuals to aid in the
diagnosis of HSV infections. The assay is not intended to be used
for prenatal screening. The ARIES® HSV 1&2 Assay is
indicated for use on the ARIES® System.
About NxTAG
The NxTAG Respiratory Pathogen
Panel is CE-marked in Europe, and FDA-cleared in
the U.S. The NxTAG Respiratory Pathogen Panel is an assay
that detects 20 relevant viral and bacterial respiratory pathogens,
including the atypical bacteria Chlamydophila
pneumoniae, and Mycoplasma pneumoniae. The panel is
the only respiratory assay that enables laboratories to easily and
simultaneously detect these respiratory pathogens in a single,
closed tube system and in a format that scales to accommodate
changes in throughput needed to respond to seasonal changes in
demand, especially during flu season. The NxTAG Respiratory
Pathogen Panel requires only minutes of hands-on time with no
upstream reagent preparation. The innovative tube strip design
offers laboratories the flexibility to process a single sample or
up to 96 samples per run, without wasting consumables or reagents.
Total turnaround time is only about three hours for 96 samples
(excluding extraction).
About Luminex Corporation
Luminex is committed to
applying its passion for innovation toward creating breakthrough
solutions to improve health and advance science. The company is
transforming global healthcare and life-science research through
the development, manufacturing and marketing of proprietary
instruments and assays utilizing xMAP® open-architecture
multi-analyte platform, MultiCode® real-time polymerase chain
reaction (PCR), and multiplex PCR-based technologies, that deliver
cost-effective rapid results to clinicians and researchers.
Luminex's technology is commercially available worldwide and in use
in leading clinical laboratories, as well as major pharmaceutical,
diagnostic, biotechnology and life-science companies. Luminex is
meeting the needs of customers in markets as diverse as clinical
diagnostics, pharmaceutical drug discovery, biomedical research
including genomic and proteomic research, personalized medicine,
biodefense research and food safety. For further information on
Luminex Corporation and the latest advances in multiplexing using
award winning technology, please visit
http://www.luminexcorp.com/.
Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements.
Forward-looking statements in this release include statements
regarding the development and testing progress of our pipeline
products, and the regulatory approvals thereof. The words
"believe", "expect", "intend", "anticipates", "confident", "will",
"could", "should", and similar expressions are intended to
further identify such forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995. It is
important to note that the Company's actual results or performance
could differ materially from those anticipated in such
forward-looking statements. Factors that could cause Luminex's
actual results or performance to differ materially include risks
and uncertainties relating to, among others, our ability to launch
products on time, the timing of regulatory approvals, the outcome
of clinical trials as well as the risks discussed under the heading
"Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as
filed with the Securities and Exchange Commission. The forward
looking statements contained herein represent the judgment of
Luminex as of the date of this press release, and Luminex expressly
disclaims any intent, obligation or undertaking to release publicly
any updates or revisions to any forward-looking statements to
reflect any change in Luminex's expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statements are based.
Investor Contact
Harriss
Currie
Sr. Vice President of Finance and CFO
512.219.8020
hcurrie@luminexcorp.com
Media Contact
Christine
Valle
Sr. Manager, Global Marketing
512.219.8020
cvalle@luminexcorp.com
Photo - http://photos.prnewswire.com/prnh/20160516/367923
Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/luminex-to-highlight-latest-additions-to-product-portfolio-at-the-2016-clinical-virology-symposium-300269148.html
SOURCE Luminex Corporation